Mindmed and liechti lab publish first human data on the interacting effects of an ssri and psilocybin

New york, nov. 30, 2021 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (de: mmq); (the "company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the publication of the first data on the interaction of the selective serotonin uptake inhibitor (ssri) escitalopram with the acute response to psilocybin in humans. the publication resulted from a randomized, double-blind, placebo-controlled, crossover pharmacology study in healthy volunteers conducted by the university hospital basel liechti lab and sponsored by mindmed.
MNMD Ratings Summary
MNMD Quant Ranking